[Initial experience in laparoscopic retroperitoneal lymphadenectomy for the management of nonseminomatous testicular cancer].
BACKGROUND
Germ cell tumors of the testis represent 1% of all cancers in males. The mean age of occurrence is between 15 and 35 years. Early diagnosis and accuracy of staging are factors that have an impact in survival. According with stage I SO in nonseminoma tumors, there are three management options. Choice among them is based on the risk of recurrence, their morbidity and informed consent of the patient. The objective of this paper is to present the first results of retroperitoneal laparoscopic lymphadenectomy (RLL) in testicular germ cell nonseminoma tumors stage I S-0 at the Oncology Unit of Hospital Juarez de México.


METHODS
Retrospective study of the data base of patients diagnosed with nonseminomatous testicular cancer Stage I, S-0 and subject to retroperitoneal laparoscopic lymphadenectomy in the period between May 2010 to December 2011.


RESULTS
Ten patients underwent transperitoneal retroperitoneal laparoscopic lymphadenectomy with modified limits, ipsilateral to the affected testicle, 70% were stage I-A, showing a nodal count of 15.3 nodes. None suffered from metastases. The followup mean for all patients was 9.6 months. One patient suffered retroperitoneal relapse off lymphadenectomy's reach 10 months after the original surgery.


CONCLUSIONS
Retroperitoneal laparoscopic lymphadenectomy is a safe procedure with reasonable morbidity, hospital stay and nodal count. It requires a surgeon expert in laparoscopic techniques.
Unidad de Oncología, Hospital Juárez de México, México, D.F., Mexico. eriksosa2011@hotmail.com
Erik Efraín
EE
Sosa-Durán
Ziad Abo
ZA
Harp-Hasan
Francisco Mario
FM
García-Rodríguez
Alberto Bazán
AB
Soto
María de Los Dolores
Mde L
Delgado-Ochoa
Xicotencatl
X
Jiménez-Villanueva
D000328:Adult; D014408:Biomarkers, Tumor; D016063:Blood Loss, Surgical; D018236:Carcinoma, Embryonal / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D017024:Chemotherapy, Adjuvant; D006063:Chorionic Gonadotropin / Q000097:blood; D003131:Combined Modality Therapy; D059247:Fertility Preservation; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood; D010535:Laparoscopy / Q000379:methods*; D007902:Length of Stay / Q000706:statistics & numerical data; D008197:Lymph Node Excision / Q000379:methods*; D008297:Male; D019060:Minimally Invasive Surgical Procedures; D009367:Neoplasm Staging; D009919:Orchiectomy; D011300:Preoperative Care; D012187:Retroperitoneal Space; D012189:Retrospective Studies; D013736:Testicular Neoplasms / Q000097:blood / Q000188:drug therapy / Q000473:pathology / Q000601:surgery*; D055815:Young Adult; D000509:alpha-Fetoproteins / Q000032:analysis
D014408:Biomarkers, Tumor; D006063:Chorionic Gonadotropin; D000509:alpha-Fetoproteins; D007770:L-Lactate Dehydrogenase